

1 **Clinical Characteristics and Risk Factors for Myocardial Injury and**
2 **Arrhythmia in COVID-19 patients**

3 Hong Gang Ren^{1,2}, Xingyi Guo², Lei Tu³, Qinyong Hu⁴, Kevin Blighe⁵, Luqman
4 Bin Safdar⁶, Justin Stebbing⁷, Shepard D Weiner⁸, Monte S Willis⁹, Frits R
5 Rosendaal¹⁰, Guogang Xu¹¹, Feng Cao¹¹, Dao Weng Wang¹²

6 ¹Department of Internal Medicine, Tongji Hospital, Tongji Medical College,
7 Huazhong University of Science and Technology, Wuhan, China.

8 ²Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology
9 Center, Vanderbilt University School of Medicine, Nashville, TN, USA.

10 ³Division of Gastroenterology, Union Hospital, Tongji Medical college,
11 Huazhong University of Science and Technology, Wuhan, China.

12 ⁴Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.

13 ⁵Clinical Bioinformatics Research Ltd., London, UK.

14 ⁶The Ministry of Agriculture and Rural Affairs, Wuhan 430062, China.

15 ⁷Department of Surgery and Cancer, Division of Cancer, Imperial College
16 London, Hammersmith Hospital Campus, Du Cane Road, London, UK.

17 ⁸Division of Cardiology, Department of Medicine, Columbia University Medical
18 Center, New York, NY, USA.

19 ⁹Section of Cardiology, Department of Pathology and Laboratory Medicine,
20 Indiana University School of Medicine, Indianapolis, Indiana, USA.

21 ¹⁰Department of Clinical Epidemiology and Department of Thrombosis and
22 Haemostasis, Leiden University Medical Center, Leiden, The Netherlands.

23 ¹¹The Second Medical Center & National Clinical Research Center for Geriatric
24 Diseases, Chinese PLA General Hospital, Beijing, China.

25 ¹²Cardiovascular Department, Tongji Medical College, Huazhong University of
26 Science and Technology, Wuhan, China.

27 **Corresponding Authors:**

28 **Prof. Feng Cao**, E-mail address: fengcao8828@163.com

29 **Prof. Dao Weng Wang**, E-mail address: daowen.wang@foxmail.com

30 **Disclosure:** the authors have nothing to disclose.

WITHDRAWN
see manuscript DOI for details

31 **ABSTRACT**

32 **Background:** Patients with COVID-19 can develop myocardial injury and
33 arrhythmia during the course of their illness. However, the underlying risk
34 factors for the development of cardiovascular related manifestations are
35 unclear.

36 **Methods:** Using a register-based multi-center cross-sectional design, we
37 analyzed 80 patients with myocardial injury and 401 controls, as well as 71
38 patients with arrhythmia and 409 controls, all admitted with COVID-19.
39 Putative risk factors for myocardial injury and arrhythmia were evaluated with
40 logistic regression with adjustment for potential confounders.

41 **Results:** COVID-19 patients with myocardial injury had fatigue (66.2%) and
42 dyspnea (63.7%), while those with arrhythmia had dyspnea (71.8%). Patients
43 with myocardial injury and arrhythmia had a significant mortality of 92.5% and
44 94.4%, respectively. A history of chronic obstructive pulmonary disease (COPD)
45 or heart diseases was associated with an increased risk of myocardial injury
46 (odds ratio [OR] = 1.94, 95% confidence interval [CI]: 1.01-3.71; OR = 7.43, 95%
47 CI: 3.99-13.83) and arrhythmia (OR = 1.94, 95% CI: 1.00-3.75; OR = 13.16, 95%
48 CI: 6.75-25.68). In addition, we found that gamma glutamyltranspeptidase
49 (GGT) >50U/L (OR = 2.14, 95% CI: 1.37-3.32; OR = 1.85, 95% CI: 1.19-2.85),
50 serum creatinine >111 μ mol/L (OR = 8.96, 95% CI: 4.4-18.23; OR = 3.71, 95%
51 CI: 2.01-6.85), serum sodium <136 mmol/L (OR = 4.68, 95% CI: 2.46-8.91; OR
52 = 2.06; 95% CI: 1.06-4.00) were all associated with increased risk of
53 myocardial injury and arrhythmia, respectively.

54 **Conclusion:** Our reported clinical characteristics and identified risk factors are
55 important for clinical study of COVID-19 patients developing myocardial injury
56 and arrhythmia.

57

58 INTRODUCTION

59 The outbreak of new coronavirus disease (COVID-19) was characterized as a
60 pandemic by World Health Organization on March 11, 2020^{1,2}. COVID-19 may
61 cause pneumonia with severe respiratory symptoms that may progress to
62 acute respiratory distress syndrome (ARDS) and even death. Common signs
63 of COVID-19 are fever, cough, muscle soreness, weakness, breathing difficulty
64 and dyspnea³. During an infection, COVID-19 patients may develop varying
65 degrees of myocardial injury³⁻⁶. In a previous study by Huang *et al.*¹, 5 out of
66 41 study participants were diagnosed with acute myocardial injury. The main
67 manifestations of acute myocardial injury have been hypersensitive cardiac
68 aggregates, troponin I (hs-cTnI) and elevated blood pressure. Most patients
69 with significant myocardial injury required treatment in the Intensive Care Unit
70 (ICU)³⁻⁶. Other studies have shown that plasma biomarkers of myocardial
71 injury, including creatine kinase (CK-MB), and troponin I were higher in ICU
72 patients than those not treated in the ICU, providing evidence that ICU patients
73 are more likely to develop cardiac complications such as myocardial injury³.

74 It has been suggested that systemic inflammatory responses and immune
75 system disorders lead to increased rates of cardiovascular symptoms^{1, 7-9}.
76 SARS-CoV-2 causes a severe inflammatory response, which may play a role
77 in the development of myocardial infarction and arrhythmias. In a retrospective
78 study of 138 hospitalized COVID-19 patients by Wang *et al*, nearly 17% of
79 patients developed arrhythmia and 7.2% experienced acute cardiac injury³.

80 The clinical presentation of COVID-19 patients with myocardial injury or
81 arrhythmias is different in many ways from patients without cardiac
82 involvement. Fatigue, anorexia, dyspnea, vomit and diarrhea are were more
83 commonly observed for COVID-19 patients with myocardial injury or
84 arrhythmias than the latter patients. To date, there has not been any clinical
85 research investigating the risk factors related to myocardial injury and

86 arrhythmia in patients with COVID-19. Furthermore, there are no studies which
87 explore whether or not the development of myocardial injury and arrhythmia
88 influences the prognosis of COVID-19 patients, although intuitively, one would
89 expect patients with cardiac manifestations to have a worse prognosis. Here,
90 we have recruited 481 COVID-19 patients used a registry-based multi-center
91 cross-sectional design from a retrospective study. We evaluated clinical
92 characteristics of 80 patients with myocardial injury and 71 patients with
93 arrhythmias. We further evaluated the associations of potential risk factors with
94 myocardial injury and arrhythmia caused by COVID-19.

95 **METHODS**

96 **Study design and data collection**

97 This was a retrospective cross-sectional study of medical records from three
98 medical centers in Hubei province. Oral informed consent was obtained from
99 all subjects, and the institutional review boards of all participating institutions
100 approved the study protocol. We recruited 481 admitted COVID-19 patients
101 from Wuhan Union West Hospital (n=265), Wuhan Hannan General Hospital
102 (n=153) and Enshi General Hospital (n=63) from January 8th, 2020 to April 20th,
103 2020. The end-of-study date was April 24th, 2020. We reviewed nursing charts,
104 clinical records, laboratory findings, and imaging results for patients with a
105 COVID-19 diagnosis in the three hospital systems based on the National
106 Health Commission and CDC, China protocol (the 5th edition). These data
107 have not yet been published.

108 **Study outcomes**

109 Acute myocardial injury was defined by serum levels of troponin T (TnT) at the
110 99th percentile or greater, as previously described¹. Malignant arrhythmia was
111 defined as rapid ventricular tachycardia lasting more than 30 seconds,
112 inducing hemodynamic instability and/or ventricular fibrillation, as per the

113 American College of Cardiology/American Heart Association Task Force on
114 Clinical Data Standards (ACC/AHA/HRS). Health services utilization patterns
115 were analyzed as binary variables (yes or no) to ventilation, antibiotics,
116 antifungals, antiviral agents and hemodialysis.

117 The following demographic and clinical features were identified from patients'
118 medical records: socio-demographic variables included sex (male and female),
119 race (Han, others), age (continuous variable), and smoking. Disease severities
120 included the number of symptoms, unilateral or bilateral infection, and imaging
121 characteristics (ground-glass opacification/opacity, yes/no). Comorbidity
122 variables included cardiovascular diseases such as hypertension, underlying
123 heart disease and coronary artery disease, chronic kidney and/or liver disease,
124 chronic obstructive airways disease (COPD), diabetes and others. Laboratory
125 tests analyzed included complete blood count, comprehensive metabolic panel
126 (CMP) and clotting factors.

127 **Statistical Analysis**

128 Kruskal-Wallis tests were applied for continuous variables among patients
129 from the three different regions. Categorical variables were displayed as
130 counts or percentages. Chi-square tests were applied for categorical variables
131 among patients from different regions. The associations of risk factors with
132 myocardial injury and arrhythmia were evaluated using logistic regression
133 models with an adjustment of potential confounders including after adjusting
134 for age, gender, smoking status, and disease history. Continuous variables
135 were summarized as medians. All statistical analyses were implemented using
136 SAS, version 9.4 (SAS Institute, Inc.). A *P* value <0.05 for a two-tailed test was
137 considered statistically significant.

138 **RESULTS**

139 **Clinic characteristics of study participants with myocardial injury**

140 Socio-demographic and clinical characteristics of the 481 study participants
141 including 80 cases of myocardial injury and 401 controls, were shown in Table
142 1. The median age (SD) of the study participants was 56. Of the patients with
143 myocardial injury, 66.2% had fatigue and 63.7% had dyspnea. Disease
144 severity was more likely to be higher in patients with myocardial injury (2.5%
145 were mild, 2.5% were moderate and 95% were severe, $P < 0.001$). In contrast,
146 2/3 of the control subjects had mild disease. Of the patients with myocardial
147 injury, 7.5% recovered and were discharged from hospital, while 92.5% died
148 ($P < 0.001$).

149 We observed that age was associated with an increased risk of myocardial
150 injury case ($P < 0.01$; Table 1). We also observed that there was a male
151 predominance for myocardial injury (70% vs 30%, $P = 0.003$; Table 1). There
152 was no such male predominance in the control group. No significant
153 associations with myocardial injury were observed for smoking status and
154 maximum temperature during fever.

155 **Multivariate analysis between laboratory parameters and myocardial** 156 **injury**

157 Patients with an abnormal GGT were associated with an increased risk of
158 developing myocardial injury (OR = 2.14, 95% CI: 1.37-3.32; Table 2).
159 Elevated serum creatinine (adjusted OR = 8.96, 95% CI: 4.4-18.23) and
160 reduced serum sodium (adjusted OR = 4.68, 95% CI: 2.46-8.91) were also
161 associated with an increased risk of myocardial injury. However, white blood
162 cell count, lymphocyte count, total bilirubin, alanine aminotransferase,
163 aspartate aminotransferase (AST) and blood urea nitrogen (BUN) did not
164 appear to be associated with the risk of myocardial injury. In addition to these
165 laboratory parameters, we observed that the uses of antibiotics (adjusted OR =
166 3.07, 95% CI: 1.58-5.95) and antiviral therapy (OR = 2.18, 95% CI: 1.2-3.93)
167 were associated with an increased risk of myocardial injury. However, AST,

168 albumin, BUN did not appear to be associated with the risk of malignant
169 arrhythmia caused by COVID-19.

170 **Clinic characteristics of study participants with arrhythmias**

171 Socio-demographic and clinical characteristics of 71 cases of arrhythmia and
172 409 controls, were analyzed (Table 1). Patients with arrhythmia (Median
173 age=61) had significantly older than controls (Median age=56) – 66.2% of
174 cases were male. No significant differences were found for smoking status and
175 highest fever between cases and controls.

176 Of the 71 arrhythmia cases, 71.8% had dyspnea – 95.8% participants with
177 arrhythmia were classified as having severe COVID-19 disease. The outcome
178 of patients with arrhythmia was poor, with only 5.6% recovering and being
179 discharges and 94.4% dead ($P<0.001$).

180 **Multivariate analysis of laboratory parameters with arrhythmias**

181 Table 2 illustrates the association between different laboratory parameters and
182 arrhythmias. Patients with increased GGT had a 1.85-fold increase in risk of
183 arrhythmias when compared with those with normal GGT (95% CI:1.19-2.85).
184 In addition, the elevated serum sodium was associated with increased risk of
185 arrhythmia (adjusted OR = 2.06, 95% CI:1.06-4.00). In addition to these
186 laboratory parameters, we observed that the uses of oxygen therapy (adjusted
187 OR = 3.11, 95%CI: 1.65-5.83) and antibiotic therapy (OR = 2.03, 95% CI:
188 1.1-3.76) were associated with an increased risk of arrhythmia. However, AST,
189 albumin, and BUN did not appear to be associated with the risk of arrhythmia
190 caused by COVID-19 as well.

191 **DISCUSSION**

192 In a large study of Covid-19 patients with and without myocardial injury and
193 arrhythmia we found that older age, male sex, history of COPD and heart
194 diseases, electrolyte disturbance and renal dysfunction were associated .With

195 the exception of asymptomatic carriers, most COVID-19 patients may develop
196 pneumonia with severe respiratory symptoms^{1, 10}. The more severe cases
197 progress to multiple organ failure or even death.

198 It is believed that a cytokine release syndrome or cytokine storm which is
199 triggered by the host response to the virus is responsible for acute injury to
200 multiple organ systems including the heart, liver, and kidneys. It is becoming
201 apparent that cardiovascular disease resulting from COVID-19 is not as
202 uncommon as previously thought, and that the involvement of the heart prone
203 to more severe disease and increased mortality. Thus, the identification of risk
204 factors for arrhythmias and acute myocardial injury is important for
205 prognostication, in addition to early intervention, early diagnosis and treatment,
206 which may help reduce morbidity and mortality.

207 A previous study showed that 53.3% of COVID-19 patients with heart damage
208 were men. In that study, myocardial injury was negatively correlated with age
209 and the incidence of myocardial injury was lowest over the age of eighty. In our
210 study, indicators of cardiac injury were generally negative in the patients with
211 mild and moderate disease. AST, LDH, CTN I and MYO showed a strong
212 correlation with myocardial injury. This is consistent with the results of Zhong *et*
213 *al.*¹¹. We also found that patients who were not treated with glucocorticoids
214 (GCs) and immunoglobulin therapy appeared to be at higher risk for heart
215 damage. The protective role of GCs may be related to their
216 immunosuppressive effects on leukocytes and endothelial cells to reduce the
217 generation and release of pro-inflammatory cytokines that
218 target cardiomyocytes¹². The glucocorticoid receptor (GR) is expressed
219 abundantly in cardiomyocytes, and the variability of acute cardiac injury may
220 be related to polymorphisms of the glucocorticoid receptor. In addition, the GR
221 can be selectively activated and cyclooxygenase (COX)-2 and prostaglandin
222 (PG) biosynthesis in cardiomyocytes can be induced, which may help mediate
223 cardioprotection^{13, 14}. Biosynthesis of prostaglandin can inhibit COX-2, and,

224 therefore, relieve inflammation derived myocardial damage in COVID-19
225 patients.

226 We found that white blood cell numbers, lymphocyte numbers, neutrophil
227 numbers, albumin, total bilirubin, alanine aminotransferase, AST, serum
228 sodium, BUN, serum creatinine, GGT and myoglobin were positively
229 correlated with myocardial injury. Elevated neutrophil counts led to a 3.35-fold
230 increase in acute cardiac injury. Neutrophils are often the first type of leukocyte
231 that infiltrate the heart in times of hyperimmune status. Their activation
232 produces large amounts of inflammatory mediators, which mediate injury to
233 the heart through the action of reactive oxygen species and proteolytic
234 enzymes, leading to reduced oxygenation of the heart tissue¹⁵⁻¹⁷. Neutrophils
235 can also induce migration of They are also involved in macrophage migration
236 to the infarct site in order to clear debris. The inflammatory process induced by
237 neutrophils involves a process known as netosis through the generation of
238 neutrophil extracellular traps (NETs).

239 We observed a negative correlation between albumin levels and risk of
240 myocardial injury. This relationship has never been reported¹⁸. Serum albumin
241 (SA) may exert a cardio-protective effect by functioning as a natural inhibitor of
242 the angiotensin-converting enzyme (ACE). ACE activity has also been
243 associated with coronary vascular resistance in recent animal studies. The
244 cardio-protective effect of ACE inhibition in cardiac surgery has been
245 previously demonstrated¹⁹⁻²³. Within the physiological range of SA
246 concentrations (35-52 mg/ml), almost all ACE is bound to albumin (and thus
247 inactive). Below the physiological range of SA concentrations there is a rapid
248 increase in the fraction of unbound (and thus active) ACE. The drop in SA in
249 patients with heart damage is an important observation with potential
250 therapeutic implications, including the close monitoring of albumin in patients
251 admitted for COVID-19 pneumonia. Myoglobin, a useful marker of cardiac
252 damage, has also been positively associated with a risk of heart damage²⁴.

253 In our study, the arrhythmia group had a higher number of elderly subjects
254 (except for age >80), whereas in the control group, there was an equal
255 distribution in the <40, 40-60- and 60-80-year age categories. AST, LDH, CTN
256 I and MYO also showed a strong correlation with arrhythmia. Patients who
257 were not treated with glucocorticoids (GCs) and immunotherapy had a higher
258 incidence of arrhythmias, in concert with the observations in myocardial injury,
259 most likely through the same anti-inflammatory mechanism.

260 **LIMITATIONS**

261 One important limitation of our study is that it does not fully elaborate on
262 whether patients were admitted to hospital with cardiac disease already, which
263 could mean that we would be studying the consequences of cardiac disease
264 rather than risk factors for cardiac disease. Although, we do attempt to
265 elucidate this via each respective patient's medical history. In our study, timing
266 is also crucial: our study is not strictly a cross-sectional study where variables
267 present at the same time were observed - this study is about patients who all
268 had COVID-19, and some also had heart disease around that time. It is
269 important to know whether heart disease began before or after admission for
270 COVID-19.

271 **CONCLUSION**

272 In conclusion, our study produced valuable clinical data related to the study of
273 myocardial injury and arrhythmias in COVID-19 patients. We identified several
274 risk factors associated with myocardial injury and arrhythmias in COVID-19
275 patients. Our findings provide potential markers for the further development of
276 clinical guidance and treatment for COVID-19 patients with a considerable risk
277 of developing severe cardiac manifestations.

278 **Declaration of interests:** All authors declare no competing interests.

279 **Acknowledgments:** We thank all the patients and their families, and the

280 clinical staff who treated the patients in Hannan, Enshi and Union medical
281 centres. We would also like to thank Troy Gharibani at University of Maryland,
282 USA for editing and providing feedback on this article.
283

WITHDRAWN
see manuscript DOI for details

284 **References**

- 285 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X,
286 Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H,
287 Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features
288 of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*
289 2020;**395**(10223):497-506.
- 290 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W,
291 Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel
292 Coronavirus Investigating and Research Team. A Novel Coronavirus from
293 Patients with Pneumonia in China, 2019. *The New England journal of medicine*
294 2020;**382**(8):727-733.
- 295 3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z,
296 Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138
297 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
298 Wuhan, China. *JAMA* 2020.
- 299 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X,
300 Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical
301 course and risk factors for mortality of adult inpatients with COVID-19 in
302 Wuhan, China: a retrospective cohort study. *Lancet*
303 2020;**395**(10229):1054-1062.
- 304 5. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q,
305 Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in
306 Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA cardiology*
307 2020.
- 308 6. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu
309 Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus
310 Disease 2019 (COVID-19). *JAMA cardiology* 2020.

- 311 7. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ.
312 Cardiac complications in patients with community-acquired pneumonia:
313 incidence, timing, risk factors, and association with short-term mortality.
314 *Circulation* 2012;**125**(6):773-81.
- 315 8. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H,
316 Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS.
317 Pathological findings of COVID-19 associated with acute respiratory distress
318 syndrome. *The Lancet. Respiratory medicine* 2020;**8**(4):420-422.
- 319 9. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk
320 of myocardial infarction and stroke after acute infection or vaccination. *The*
321 *New England journal of medicine* 2004;**351**(25):2611-8.
- 322 10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei
323 Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of
324 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
325 study. *Lancet* 2020;**395**(10223):507-513.
- 326 11. Guan WJ, Zhong NS. Clinical Characteristics of Covid-19 in China. Reply.
327 *The New England journal of medicine* 2020;**382**.
- 328 12. Tokudome S, Sano M, Shinmura K, Matsuhashi T, Morizane S, Moriyama
329 H, Tamaki K, Hayashida K, Nakanishi H, Yoshikawa N, Shimizu N, Endo J,
330 Katayama T, Murata M, Yuasa S, Kaneda R, Tomita K, Eguchi N, Urade Y,
331 Asano K, Utsunomiya Y, Suzuki T, Taguchi R, Tanaka H, Fukuda K.
332 Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by
333 activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis.
334 *The Journal of clinical investigation* 2009;**119**(6):1477-88.
- 335 13. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ.
336 Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury
337 in vivo. *The Journal of clinical investigation* 2001;**108**(4):585-90.

- 338 14. Takahashi T, Zhu SJ, Sumino H, Saegusa S, Nakahashi T, Iwai K,
339 Morimoto S, Kanda T. Inhibition of cyclooxygenase-2 enhances myocardial
340 damage in a mouse model of viral myocarditis. *Life sciences*
341 2005;**78**(2):195-204.
- 342 15. Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, Mukhametshina RT,
343 Kwek XY, Cabrera-Fuentes HA, Hausenloy DJ. Inflammation following acute
344 myocardial infarction: Multiple players, dynamic roles, and novel therapeutic
345 opportunities. *Pharmacology & therapeutics* 2018;**186**:73-87.
- 346 16. Karakas MS, Korucuk N, Tosun V, Altekin RE, Koç F, Ozbek SC, Ozel D,
347 Ermis C. Red cell distribution width and neutrophil-to-lymphocyte ratio predict
348 left ventricular dysfunction in acute anterior ST-segment elevation myocardial
349 infarction. *Journal of the Saudi Heart Association* 2016;**28**(3):152-8.
- 350 17. Williams BA, Merhige ME. Association between neutrophil-lymphocyte
351 ratio and impaired myocardial perfusion in patients with known or suspected
352 coronary disease. *Heart & lung : the journal of critical care* 2013;**42**(6):436-41.
- 353 18. van Beek D, van der Horst I, de Geus AF, Mariani MA, Scheeren T.
354 Albumin, a marker for post-operative myocardial damage in cardiac surgery.
355 *Journal of critical care* 2018;**47**:55-60.
- 356 19. Fagyas M, Úri K, Siket IM, Fülöp GÁ, Csató V, Daragó A, Boczán J, Bányai
357 E, Szentkirályi IE, Maros TM, Szerafin T, Édes I, Papp Z, Tóth A. New
358 perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin
359 suppresses angiotensin converting enzyme (ACE) activity in human. *PLoS one*
360 2014;**9**(4):e87844.
- 361 20. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting
362 enzyme inhibitors on mortality and morbidity in patients with heart failure.
363 Collaborative Group on ACE Inhibitor Trials. *JAMA* 1995;**273**(18):1450-6.
- 364 21. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S.

- 365 Angiotensin-converting-enzyme inhibitors in stable vascular disease without
366 left ventricular systolic dysfunction or heart failure: a combined analysis of
367 three trials. *Lancet* 2006;**368**(9535):581-8.
- 368 22. Lazar HL, Volpe C, Bao Y, Rivers S, Vita JA, Keaney JF Jr. Beneficial
369 effects of angiotensin-converting enzyme inhibitors during acute
370 revascularization. *The Annals of thoracic surgery* 1998;**66**(2):487-92.
- 371 23. Lazar HL, Bao Y, Rivers S, Bernard SA. Pretreatment with
372 angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion
373 injury. *The Annals of thoracic surgery* 2002;**73**(5):1522-7.
- 374 24. Furuhashi M, Ura N, Hasegawa K, Yoshida H, Tsuchihashi K, Nakata T,
375 Shimamoto K. Serum ratio of heart-type fatty acid-binding protein to myoglobin.
376 A novel marker of cardiac damage and volume overload in hemodialysis
377 patients. *Nephron. Clinical practice* 2003;**93**(2):C69-74.

378

Table 1. Clinic Characteristics of Study Participants on Myocardial Injury and Arrhythmia

Characteristic	Myocardial Injury		Arrhythmia	
	Yes	No	Yes	No
Number (%)	80	401	71	410
Age (years)				
≤40	3 (3.8)	110 (27.4)	2 (2.8)	111 (27.1)
40-59	12 (15.0)	148 (36.9)	15 (21.1)	145 (35.4)
60-79	52 (65.0)	128 (31.9)	44 (62.0)	136 (33.2)
≥80	13 (16.2)	15 (3.7)	10 (14.1)	18 (4.4)
Sex				
Female	24 (30.0)	196 (48.9)	24 (33.8)	196 (47.8)
Male	56 (70.0)	205 (51.1)	47 (66.2)	214 (52.2)
Smoking status				
Never	69 (86.2)	372 (92.8)	64 (90.1)	377 (92.0)
Current	10 (12.5)	27 (6.7)	6 (8.5)	31 (7.6)
Former	1 (1.2)	2 (0.5)	1 (1.4)	2 (0.5)
The highest temperature (Mean, SD)	38.36 (1.01)	38.05 (1.75)	38.36 (1.05)	38.06 (1.73)
Signs and symptoms				
Fatigue	53 (66.2)	191 (47.6)	39 (54.9)	205 (50.0)
Anorexia	51 (63.7)	264 (65.8)	40 (56.3)	275 (67.1)
Dyspnea	51 (63.7)	60 (15.0)	51 (71.8)	60 (14.6)
Disease severity				
Mild	2 (2.5)	270 (67.3)	3 (4.2)	269 (65.6)
General	2 (2.5)	48 (12.0)	0 (0.0)	50 (12.2)
Serious	76 (95.0)	83 (20.7)	68 (95.8)	91 (22.2)
Outcomes				
Death	74 (92.5)	73 (18.2)	67 (94.4)	80 (19.5)

Discharge	6 (7.5)	312 (77.8)	4 (5.6)	314 (76.6)
Still in hospital	0 (0.0)	16 (4.0)	0 (0.0)	16 (3.9)

380

WITHDRAWN
see manuscript DOI for details

Table 2 Multi-variable Analysis of putative risk factors for Myocardial Injury and Arrhythmia

Characteristic	Myocardial Injury		OR	Adjusted. OR	Arrhythmia		OR	Adjusted. OR
	Yes	No	(95% CI)	(95% CI)	Yes	No	(95% CI)	(95% CI)
	n=80	n=401			n=71	n=410		
Age (years)								
≤40	3 (3.8)	110 (27.4)			2 (2.8)	111 (27.1)		
40-59	12 (15.0)	148 (36.9)	2.97(0.82, 10.79)	2.07(0.55, 7.74)	15 (21.1)	145 (35.4)	5.74(1.29, 25.62)	5.07(1.12, 22.92)
60-79	52 (65.0)	128 (31.9)	14.9(4.53, 49.03)	9.78(2.85, 33.63)	44 (62.0)	136 (33.2)	17.96(4.26, 75.7)	14.59(3.35, 63.63)
≥80	13 (16.2)	15 (3.7)	31.78(8.1, 124.61)	18.85(4.37, 81.24)	10 (14.1)	18 (4.4)	30.83(6.24, 152.36)	17.51(3.23, 94.86)
Medical histories								
COPD	4 (5.0)	5 (1.2)	3.51(2, 6.16)	1.94(1.01, 3.71)	2 (2.8)	7 (1.7)	3.02(1.68, 5.45)	1.94(1, 3.75)
Heart disease	16 (20.0)	36 (9.0)	9.99(5.87, 17.02)	7.43(3.99, 13.83)	17 (23.9)	35 (8.5)	14.87(8.29, 26.7)	13.16(6.75, 25.68)
Diabetes	25 (31.2)	46 (11.5)	2.53(1.33, 4.84)	0.9(0.42, 1.9)	21 (29.6)	50 (12.2)	3.37(1.77, 6.43)	1.68(0.82, 3.43)
Hypertension	37 (46.2)	83 (20.7)	4.17(1.09, 15.88)	0.99(0.22, 4.54)	27 (38.0)	93 (22.7)	1.67(0.34, 8.2)	0.55(0.1, 3.11)
Cerebrovascular disease	9 (11.2)	7 (1.7)	3.3(2, 5.44)	1.26(0.69, 2.31)	8 (11.3)	8 (2.0)	2.09(1.23, 3.56)	0.72(0.38, 1.37)
Chronic kidney disease	7 (8.8)	10 (2.5)	7.13(2.57, 19.78)	2.06(0.65, 6.57)	5 (7.0)	12 (2.9)	6.38(2.31, 17.61)	2.78(0.87, 8.89)
Chronic liver disease	4 (5.0)	7 (1.7)	3.75(1.38, 10.17)	1.78(0.52, 6.06)	3 (4.2)	8 (2.0)	2.51(0.86, 7.36)	1.1(0.31, 3.88)
Others	15 (18.8)	48 (12.0)	2.96(0.85, 10.37)	4.73(1.07, 20.85)	6 (8.5)	57 (13.9)	2.22(0.57, 8.57)	2.54(0.6, 10.76)

Number of Comorbidities	2 (1.42)	0.75 (1.04)			1.85 (1.29)	0.80 (1.12)		
(mean, SD)								
Lab tests								
Aspartate aminotransferase (>40U/L)	42 (52.5)	121 (30.8)	1.7(0.9, 3.21)	1.33(0.61, 2.87)	37 (52.1)	126 (30.7)	0.57(0.24, 1.38)	0.3(0.11, 0.84)
Glutamyltranspeptidase (>50U/L)	21 (26.6)	96 (24.4)	2.13(1.74, 2.6)	2.14(1.37, 3.32)	17 (23.9)	100 (24.4)	1.82(1.5, 2.21)	1.85(1.19, 2.85)
Albumin (<40g/L)	66 (82.5)	103 (25.9)	2.48(1.52, 4.05)	1.5(0.85, 2.63)	50 (70.4)	119 (29.0)	2.45(1.47, 4.09)	1.48(0.84, 2.6)
Urea nitrogen (>8.1mmol/L)	41 (51.2)	43 (10.8)	1.12(0.65, 1.95)	0.97(0.52, 1.83)	27 (38.0)	57 (13.9)	0.98(0.54, 1.76)	0.84(0.44, 1.61)
Serum creatinine (>111µmol/L)	45 (56.2)	65 (16.3)	13.46(7.25, 24.98)	8.96(4.4, 18.23)	35 (49.3)	75 (18.3)	5.82(3.35, 10.12)	3.71(2.01, 6.85)
Serum sodium (<136mmol/L)	33 (41.2)	139 (35.1)	8.7(5.07, 14.95)	4.68(2.46, 8.91)	36 (50.7)	136 (33.2)	3.8(2.18, 6.62)	2.06(1.06, 4)
Treatments								
Oxygen therapy	51 (63.7)	254 (63.3)	6.61(3.95, 11.06)	4.55(2.44, 8.51)	43 (60.6)	262 (63.9)	4.34(2.56, 7.37)	3.11(1.65, 5.83)
Glucocorticoid therapy	61 (76.2)	165 (41.5)	1.3(0.79, 2.12)	0.83(0.47, 1.46)	50 (70.4)	176 (42.9)	2.07(1.25, 3.45)	1.43(0.82, 2.5)
Immunoglobulin therapy	39 (48.8)	109 (27.4)	1.02(0.62, 1.68)	0.75(0.42, 1.32)	26 (36.6)	122 (29.8)	0.87(0.52, 1.45)	0.63(0.36, 1.12)
Antibiotic therapy	70 (87.5)	350 (87.9)	4.53(2.61, 7.88)	3.07(1.58, 5.95)	63 (88.7)	357 (87.1)	3.17(1.83, 5.46)	2.03(1.1, 3.76)
Antiviral therapy	73 (91.2)	376 (94.5)	2.52(1.54, 4.12)	2.18(1.2, 3.93)	66 (93.0)	383 (93.4)	1.36(0.81, 2.31)	0.94(0.52, 1.72)
Outcomes								
Death	74 (92.5)	73 (18.2)			67 (94.4)	80 (19.5)		
Discharge	6 (7.5)	312 (77.8)	0.96(0.46, 1.99)	0.66(0.28, 1.57)	4 (5.6)	314 (76.6)	1.17(0.53, 2.58)	0.93(0.38, 2.28)

Still in hospital	0 (0.0)	16 (4.0)	0.61(0.25, 1.48)	0.73(0.24, 2.2)	0 (0.0)	16 (3.9)	0.93(0.35, 2.5)	1.19(0.38, 3.71)
-------------------	---------	----------	------------------	-----------------	---------	----------	-----------------	------------------

382

WITHDRAWN
see manuscript DOI for details